Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Non-Current Debt: 2021-2024

Historic Non-Current Debt for Roivant Sciences (ROIV) over the last 4 years, with Mar 2024 value amounting to $188.7 million.

  • Roivant Sciences' Non-Current Debt rose 17.88% to $191.5 million in Q2 2024 from the same period last year, while for Jun 2024 it was $191.5 million, marking a year-over-year increase of 17.88%. This contributed to the annual value of $188.7 million for FY2024, which is 17.97% up from last year.
  • Roivant Sciences' Non-Current Debt amounted to $188.7 million in FY2024, which was up 9.73% from $172.0 million recorded in FY2023.
  • In the past 5 years, Roivant Sciences' Non-Current Debt registered a high of $204.0 million during FY2021, and its lowest value of $32.6 million during FY2022.
  • For the 3-year period, Roivant Sciences' Non-Current Debt averaged around $142.1 million, with its median value being $160.0 million (2023).
  • Per our database at Business Quant, Roivant Sciences' Non-Current Debt tumbled by 80.84% in 2022 and then skyrocketed by 390.38% in 2023.
  • Over the past 4 years, Roivant Sciences' Non-Current Debt (Yearly) stood at $170.3 million in 2021, then reached $204.0 million in 2021, then slumped by 80.84% to $32.6 million in 2022, then declined by 22.88% to $157.4 million in 2022, then spiked by 390.38% to $160.0 million in 2023, then grew by 9.30% to $172.0 million in 2023, then rose by 17.97% to $188.7 million in 2024.